<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>337</serviceExecutionTime><Drug id="96140"><DrugName>BSP-804 series (Gram-negative bacterial infections), BioSource Pharm Inc</DrugName><DrugSynonyms><Name><Value>BSP-804 series (Gram-negative bacterial infections), BioSource Pharm Inc</Value></Name></DrugSynonyms><CompanyOriginator id="29277">BioSource Pharm Inc</CompanyOriginator><CompaniesSecondary><Company id="29277">BioSource Pharm Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="29277" type="Company"><TargetEntity id="5035561375" type="organizationId">BioSource Pharm Inc</TargetEntity></SourceEntity><SourceEntity id="137" type="ciIndication"><TargetEntity id="D016905" type="MeSH"></TargetEntity><TargetEntity id="-409642348" type="omicsDisease"></TargetEntity><TargetEntity id="801" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="137">Gram negative bacterium infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="66">Antibiotic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-29T16:25:45.000Z</LastModificationDate><ChangeDateLast>2018-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2018-03-20T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29277" linkType="Company"&gt;BioSource Pharm&lt;/ulink&gt; was developing BSP-804, a series of semisynthetic antibiotics, for the potential treatment of Gram-negative bacterial infections, including Pseudomonas infections. In March 2015, phase I trials were completed and phase II trials were planned and at that time, the company was seeking to outlicense its programs [&lt;ulink linkID="1646529" linkType="Reference"&gt;1646529&lt;/ulink&gt;]. However in June 2016, the company was dissolved [&lt;ulink linkID="2038184" linkType="Reference"&gt;2038184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also developing &lt;ulink linkID="72305" linkType="Drug"&gt;BSP-C801&lt;/ulink&gt; series and an analog of polymyxin B, &lt;ulink linkID="61274" linkType="Drug"&gt;CB-182804&lt;/ulink&gt;,  in collaboration with &lt;ulink linkID="21697" linkType="Company"&gt;Cubist Pharmaceuticals&lt;/ulink&gt; for multidrug-resistant Gram-negative bacterial infections.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2015, phase I trials were completed and phase II trials were planned  [&lt;ulink linkID="1646529" linkType="Reference"&gt;1646529&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29277">BioSource Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2016-06-29T00:00:00.000Z</StatusDate><Source id="2038184" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29277">BioSource Pharm Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1646529" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>